Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Psoriasis Treatments

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

New Standards of Care in ALK-Translocated Advanced NSCLC

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

PARP Inhibitors and Cancer: What Do You Need to Know?

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Patient and Clinician Perspectives on Preventive Therapy for Migraine

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

Going Beyond EXTREME in Head and Neck Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Pembrolizumab: KEYNOTE 012

Pembrolizumab: KEYNOTE 055

Case 1: 59-Year-Old Woman With Locally Advanced Hypopharyngeal Cancer

Case 1: First Steps

Case 1 (cont)

Case 1: Checkpoint Inhibition

Case 1: Follow-Up

Further Thoughts

Case 2: 44-Year-Old Man With Locally Advanced Tonsil Cancer

Significance of HPV

Case 2: Treatment

Case 2: Further Details

Addressing Patient Requests

Immunotherapy Clinical Trials in the Curative Setting

Immunotherapy Clinical Trials of First-Line Therapy in the Recurrent and/or Metastatic Setting

Other Immunotherapeutic Approaches Under Investigation

Thoughts for the Future

Conclusions

Abbreviations